TY - JOUR
T1 - Mesothelin expression and survival outcomes in triple receptor negative breast cancer
AU - Parinyanitikul, Napa
AU - Blumenschein, George R.
AU - Wu, Yun
AU - Lei, Xiudong
AU - Chavez-Macgregor, Mariana
AU - Smart, Melody
AU - Gonzalez-Angulo, Ana Maria
N1 - Funding Information:
G. R. Blumenschein and M. Smart receive research funding from Bayer . The remaining authors have stated that they have no conflicts of interest.
Funding Information:
This work was supported in part by K23CA121994-01 (A.M.G.), an American Cancer Society Research Scholar Grant 121329-RSG-11-187-01-TBG (A.M.G.), and the National Cancer Institute through The University of Texas MD Anderson Cancer Center Support Grant ( P30 CA016672 ).
PY - 2013/10
Y1 - 2013/10
N2 - Background: Mesothelin is an ideal tumor-associated marker for the development of targeted therapy due to its limited expression in normal tissues. The aim of this study was to evaluate mesothelin expression in triple-negative breast cancer (TNBC) and its correlation with survival outcomes. Methods: Mesothelin expression was completed by using immunohistochemistry and was quantified by the H score. An H score > 10 was considered positive. Patient characteristics were compared by mesothelin expression. The Kaplan-Meier product limit method was used to estimate survival outcomes. Cox proportional hazards models was used to adjust for patient and tumor characteristics. Results: The median age was 52 years. Of the 109 patients with TNBC, 37 (34%) were positive for mesothelin expression. There were no differences on patient and/or tumor characteristics by mesothelin expression with the exception of high frequency of lymphovascular space invasion in mesothelin-negative tumors (2P =.03). At a median follow-up of 75.8 months, 20 (18.3%) patients had experienced a recurrence, and 22 (20.2%) had died. Five-year progression-free survival was 87% and 92% in patients with mesothelin-positive and those with mesothelin-negative tumors (2P =.43). Five-year overall survival was 85% and 91% in patients with mesothelin-positive and those with mesothelin-negative tumors (2P =.57), respectively. Mesothelin expression was not an independent predictor of survival outcomes. Conclusion: Mesothelin expression was identified in 34% of patients with TNBC. Mesothelin expression did not correlate with survival outcomes in patients with TNBC.
AB - Background: Mesothelin is an ideal tumor-associated marker for the development of targeted therapy due to its limited expression in normal tissues. The aim of this study was to evaluate mesothelin expression in triple-negative breast cancer (TNBC) and its correlation with survival outcomes. Methods: Mesothelin expression was completed by using immunohistochemistry and was quantified by the H score. An H score > 10 was considered positive. Patient characteristics were compared by mesothelin expression. The Kaplan-Meier product limit method was used to estimate survival outcomes. Cox proportional hazards models was used to adjust for patient and tumor characteristics. Results: The median age was 52 years. Of the 109 patients with TNBC, 37 (34%) were positive for mesothelin expression. There were no differences on patient and/or tumor characteristics by mesothelin expression with the exception of high frequency of lymphovascular space invasion in mesothelin-negative tumors (2P =.03). At a median follow-up of 75.8 months, 20 (18.3%) patients had experienced a recurrence, and 22 (20.2%) had died. Five-year progression-free survival was 87% and 92% in patients with mesothelin-positive and those with mesothelin-negative tumors (2P =.43). Five-year overall survival was 85% and 91% in patients with mesothelin-positive and those with mesothelin-negative tumors (2P =.57), respectively. Mesothelin expression was not an independent predictor of survival outcomes. Conclusion: Mesothelin expression was identified in 34% of patients with TNBC. Mesothelin expression did not correlate with survival outcomes in patients with TNBC.
KW - Mesothelin expression
KW - Prognosis
KW - Triple-negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=84883762546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84883762546&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2013.05.001
DO - 10.1016/j.clbc.2013.05.001
M3 - Article
C2 - 23810431
AN - SCOPUS:84883762546
SN - 1526-8209
VL - 13
SP - 378
EP - 384
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 5
ER -